Natera To Feature Expanded Panorama® Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting
SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded Panorama® non-invasive prenatal test (NIPT), which is now validated for screening twin pregnancies, at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in Dallas, Jan. 29 to Feb. 3, 2018 (booth No. 161).
Panorama® is the first NIPT that can screen twin pregnancies for zygosity (identical or non-identical twins) and determine gender for each twin as early as 9 weeks' gestation. It is the only NIPT that differentiates between maternal and fetal DNA, which enables women to learn more about their pregnancies through a simple blood draw from the mother, posing no risk to the babies.
Vistara, an NIPT that screens single-gene disorders and was launched in mid-2017, also will be showcased at the meeting. The test complements Panorama and screens for conditions that have a combined incidence rate of 1 in 600, which is higher than that of Down syndrome.1,2
"We look forward to sharing our new NIPT technology for screening twin pregnancies with maternal-fetal medicine specialists at the SMFM conference," said Kimberly Martin, M.D., Natera's Senior Medical Director for Women's Health. "Early, highly accurate zygosity screening with Panorama can help clinicians identify monochorionic pregnancies, which are at higher risk for serious medical complications such as twin-twin transfusion syndrome, and which studies show are misclassified approximately 19 percent of the time with ultrasound alone.3"
A Lunch and Learn session titled "Aneuploidy to Zygosity: Clinical advantages of SNP-based screening for twins," also will be presented by Dr. Martin on Friday, February 2. Pre-registration is required.
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on Twitter and Facebook.
Forward Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.